Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9UNH5

UPID:
CC14A_HUMAN

ALTERNATIVE NAMES:
CDC14 cell division cycle 14 homolog A

ALTERNATIVE UPACC:
Q9UNH5; A6MA65; B1AQ14; B1AQ15; O43171; O60727; O60728; Q52LH9; Q8IXX0

BACKGROUND:
The protein Dual specificity protein phosphatase CDC14A is crucial for productive cell division, ensuring proper centrosome separation and cytokinesis. It achieves this by dephosphorylating SIRT2 during early anaphase and potentially FZR1/CDH1, aiding in mitotic exit. Its role extends to maintaining normal auditory function, as evidenced by its requirement for normal hearing.

THERAPEUTIC SIGNIFICANCE:
Given CDC14A's critical function in hearing and its association with DFNB32, a form of sensorineural deafness, the protein represents a significant target for therapeutic intervention. Exploring CDC14A's mechanisms could lead to novel treatments for hearing impairment and infertility issues linked to this protein.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.